Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone
Autore:
Ferdinand, K; Saini, R; Lewin, A; Yellen, L; Barbosa, JA; Kushnir, E;
Indirizzi:
Bristol Myers Squibb Co, Pharmaceut Res Inst, Cardiovasc Clin Res, Princeton, NJ 08543 USA Bristol Myers Squibb Co Princeton NJ USA 08543 s, Princeton, NJ 08543 USA Xavier Univ Louisiana, New Orleans, LA USA Xavier Univ Louisiana New Orleans LA USA Louisiana, New Orleans, LA USA Natl Res Inst, Los Angeles, CA USA Natl Res Inst Los Angeles CA USANatl Res Inst, Los Angeles, CA USA Cardiol Associates Med Grp, San Diego, CA USA Cardiol Associates Med Grp San Diego CA USA s Med Grp, San Diego, CA USA Ctr Invest Noroeste, Tijuana, SC, Mexico Ctr Invest Noroeste Tijuana SC Mexico vest Noroeste, Tijuana, SC, Mexico Htel Clin Cordoba, Santa Rosa, Argentina Htel Clin Cordoba Santa Rosa Argentina n Cordoba, Santa Rosa, Argentina
Titolo Testata:
AMERICAN JOURNAL OF HYPERTENSION
fascicolo: 8, volume: 14, anno: 2001,
parte:, 1
pagine: 788 - 793
SICI:
0895-7061(200108)14:8<788:EASOOW>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
VASOPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE EFFICACY; LISINOPRIL;
Keywords:
hydrochlorothiazide; hypertension; omapatrilat; vasopeptidase inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
9
Recensione:
Indirizzi per estratti:
Indirizzo: Saini, R Bristol Myers Squibb Co, Pharmaceut Res Inst, Cardiovasc Clin Res, Route 206 & Provinceline Rd, Princeton, NJ 08543 USA Bristol Myers SquibbCo Route 206 & Provinceline Rd Princeton NJ USA 08543
Citazione:
K. Ferdinand et al., "Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone", AM J HYPERT, 14(8), 2001, pp. 788-793

Abstract

This multicenter, double-blind study evaluated efficacy and safety of the vasopeptidase inhibitor omapatrilat, which simultaneously inhibits neutral endopeptidase and angiotensin converting enzyme, when given in conjunction with hydrochlorothiazide (HCTZ) to subjects nonresponsive to HCTZ alone. The study enrolled 657 subjects with mild to severe hypertension. After a 2-week placebo lead-in period and a 4-week HCTZ phase. 274 subjects were randomized to receive omapatrilat (10 or 20 mg, electively titrated to 20 or 40 mg. respectively, at week 4 if seated diastolic blood pressure [SeDBP] was greater than or equal to 90 mm Hg) or matching placebo in addition to 25 mgof HCTZ as continuing therapy. The primary outcome measure was change in SeDBP from baseline to week 8. At week 8, placebo plus HCTZ-adjusted additional reductions in SeDBP in the omapatrilat 10/20 mg and 20/40 mg treatment groups (4 and 5 turn Hg, respectively) were significant (P < .001), as werechanges in seated systolic blood pressure in both omapatrilat-treated groups (7 and 10 mm Hg, respectively; P < .001). Seated diastolic blood pressure was normalized (< 90 mm Hg) in 38% of subjects in the placebo group compared to 59% and 64% of subjects in the omapatrilat groups (P less than or equal to .008). Adverse events, serious adverse events, and discontinuations attributed to adverse events were infrequent. There were no clinically relevant changes in serum creatinine or potassium. Omapatrilat was effective and well tolerated when added to HCTZ in subjects whose blood pressure was not controlled with HCTZ alone. (C) 2001 American Journal of Hypertension, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 00:59:26